- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04703608
Prevention and Treatment for COVID -19 (Severe Acute Respiratory Syndrome Coronavirus 2 SARS-CoV-2) Associated Severe Pneumonia in the Gambia (PaTS-COVID)
Prevention and Treatment for COVID -19 Associated Severe Pneumonia in The Gambia: a Single-Blinded Randomised Clinical Trial (PaTS-COVID)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The trial is adaptive in design, with the option to change the investigational products should evidence change on the benefits/harms of the interventions being trialed.
Cohort 1. Currently index cases with mild COVID-19 or moderate pneumonia will be randomized to ivermectin 0.3-0.4mg/Kg daily for 3 days (arms 1 and 2) or non-identical placebo (arm 3). Index case randomization will also include HH members who will be treated with ivermectin 0.3-0.4mg/Kg daily for 3 days (arm 1) or non-identical placebo (arms 2 and 3). All households will receive a preventative package (containing soap, bleach, cloth facemasks and instructions on their use).
Cohort 2. Patients admitted to hospital meeting WHO criteria for severe COVID-19 pneumonia will be randomized to aspirin 150mg daily or non-identical placebo for 28 days or until hospital discharge (whichever is sooner). Other care will follow National guidelines.
The study will be conducted at multiple sites in The Gambia, with the option to recruit from other West African countries should this be necessary (subject to further local ethical review/s).
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Anna Roca, PhD
- Phone Number: 2305 +220 4495442
- Email: aroca@mrc.gm
Study Contact Backup
- Name: Effua Usuf, MBChB, PhD
- Phone Number: 5014 +220 4495442
- Email: eusuf@mrc.gm
Study Locations
-
-
-
Fajara, Gambia
- Recruiting
- Mrcg@Lshtm
-
Contact:
- Effua Usuf, MBChB
- Phone Number: 5014 +2204495442-6
- Email: eusuf@mrc.gm
-
Contact:
- Behzad Nadjm, MBChB
- Phone Number: 2123 +2204495442-6
- Email: bnadjm@mrc.gm
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Cohort 1:
Index case - Individuals ≥ 5 years of age with confirmed COVID19 mild disease or moderate pneumonia defined as:
- Mild disease - Influenza like illness, with any of the following symptoms cough, fever, headache, sore throat, nasal congestion/runny nose, body pains (myalgia), fatigue (malaise), diarrhoea, abdominal pain, anorexia, nausea or vomiting without evidence of pneumonia or hypoxia
- Moderate pneumonia -Clinical signs of pneumonia (fever, cough, dyspnoea, fast breathing) with no need for supplemental oxygen (oxygen saturation ≥90%% on room air or RR between 20 and 30bpm).
Household contacts - Individuals ≥ 5 years of age living in the same household with the index cases from cohort 1 will be offered to participate into the study. Living in the same household is defined as those individuals who are planning to sleep in and eat from same 'cooking pot' during the following 2 weeks.
Cohort 2:
Individuals ≥12 years of age with suspected or confirmed COVID-19 associated severe pneumonia defined as signs of pneumonia (fever, cough, dyspnoea or fast breathing) plus one of: oxygen saturation (SpO2) <90% on room air OR respiratory rate > 30 breaths/minute
Suspected COVID-19 disease is defined as clinically or radiologically suspected as determined by the most senior clinician available:
- Clinically suspected Signs and symptoms of pneumonia (as defined above) AND patient living in or recent travel to region with community transmission OR close contact with known COVID-19 patient AND no alternative diagnosis to explain the clinical picture OR
- Radiologically suspected Typical radiological signs of COVID-19 on chest X-ray or lung ultrasound
Exclusion Criteria:
- Pregnant women will be excluded from both Cohort 1 and Cohort 2. Patients with allergies to the investigational products will be excluded Cohort 1 (Ivermectin) Lactating mothers will be excluded
Cohort 2 (aspirin):
- Taking aspirin or other non steroidal anti-inflammatory drugs for any reason.
- Any bleeding disorder (e.g. frequent nose bleeds, haemophilia)
- Active or recurrent peptic ulcer disease (defined as currently on triple therapy or had more than 1 course of triple therapy in the past 12 months. Do not count symptoms of gastritis or on omeprazole as peptic ulcer disease)
- Current active gastrointestinal haemorrhage
- Severe liver disease or severe kidney disease (severe liver disease defined as cirrhosis with portal hypertension and history of variceal bleeding; severe kidney disease defined as stage 4/5 KD, eGFR <30ml/min)
- Gout
- Suspected intra-cerebral haemorrhage
- Diagnosed with a stroke on this admission
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1 of Cohort 1
Index Case / Household members Ivermectin / Ivermectin (with preventative package)
|
Ivermectin 0.3-0.4mg/Kg
daily for 3 days.
|
Experimental: Arm 2 of Cohort 1
Index Case / Household members Ivermectin / Placebo (with preventative package)
|
Ivermectin 0.3-0.4mg/Kg
daily for 3 days.
Non-identical placebo
|
Placebo Comparator: Arm 3 of Cohort 1
Index Case / Household members Placebo / Placebo (with preventative package)
|
Non-identical placebo
|
Experimental: Arm 1 of Cohort 2
Aspirin 150mg daily for 28 days or until hospital discharge or death (whichever is sooner)
|
Aspirin 150mg daily for 28 days or until hospital discharge (whichever is sooner)
|
Placebo Comparator: Arm 2 of Cohort 2
Non identical placebo; doses as per above
|
Non-identical placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cohort 1 Index Case: Percentage of patients with COVID-19 associated mild disease/moderate pneumonia progressing to severe pneumonia [Time frame 14 days]
Time Frame: 14 days
|
Percentage of patients with COVID-19 associated mild disease/moderate pneumonia progressing within 14 days after recruitment into severe pneumonia (as per WHO definitions of severity, for each age group)
|
14 days
|
Cohort 1 Household contacts: Percentage of HH members that get infected with SARS-CoV-2 [Time frame 14 days]
Time Frame: 14 days
|
Percentage of HH members that get infected with SARS-CoV-2 during the 14 days following recruitment (defined as those RT-PCR and IgM/IgG negative at day 1 who become positive either by RT-PCR or IgM/IgG by day 14)
|
14 days
|
Cohort 2: Percentage of COVID-19 associated severe pneumonia patients worsening their condition [Time frame at discharge or day 28 (whichever is first)]
Time Frame: up to 28 days
|
Percentage of COVID-19 associated severe pneumonia patients meeting the criteria of failure defined as worsening their condition from baseline (on admission) for a period of at least 24 hours, scale as follows:
|
up to 28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cohort1 Index cases: Days from recruitment to virological clearance [Time frame 28 days]
Time Frame: 28 days
|
- Days from recruitment to virological clearance defined as one negative SARS-CoV2 virus RT-PCRs.
|
28 days
|
Days from recruitment until clinical recovery
Time Frame: 28 days
|
- Days from recruitment until clinical recovery defined as two consecutive days of no fever (T ≤37.50C) and normal respiratory rate (as per normal range for age and WHO definitions) (only once if day 28 as end of follow-up
|
28 days
|
- IgG geometric mean titre (GMT) at day 14 and 28 after recruitment [Time frame 14 days and 28 days]
Time Frame: 14 days and 28 days
|
14 days and 28 days
|
|
Household contacts IgG geometric mean titre (GMT) at day 14 after recruitment [Time frame 14 days]
Time Frame: 14 days
|
14 days
|
|
Percentage of HH members infected that develop COVID19 symptoms [Time frame 14 days]
Time Frame: 14 days
|
(defined as those asymptomatic at day 1 that become symptomatic by day 14 (COVID-19 positive either by RT-PCR or IgM/IgG and meet criteria for Cohort 1 index case or cohort 2)
|
14 days
|
Cohort 2 - Hours from recruitment to hospital discharge [Time frame at discharge]
Time Frame: up to 28 days
|
up to 28 days
|
|
- Hours of duration on oxygen supplementation [Time frame at discharge or day 28 (whichever is first)]
Time Frame: at discharge or day 28 (whichever is first)
|
at discharge or day 28 (whichever is first)
|
|
- Death ratio during hospitalization [Time frame at time of death]
Time Frame: up to 28 days
|
up to 28 days
|
|
- Death ratio at 28 days after enrolment [Time frame 28 days]
Time Frame: 28 days
|
28 days
|
|
- Death ratio at 90 days after enrolment [Time frame 90 days]
Time Frame: 90 days
|
90 days
|
|
- Occurrence of clinical thrombotic and embolic events (myocardial infarction, pulmonary embolus, deep venous thrombosis, cerebrovascular accidents). [Time frame 90 days]
Time Frame: 90 days
|
90 days
|
|
- Occurrence of clinical episodes of gastrointestinal bleeding [Time frame 90 days]
Time Frame: 90 days
|
90 days
|
|
- Change in CRP and D-Dimer levels between baseline (enrolment) and day 3-5 [Time frame 5 days]
Time Frame: enrolment / days 3-5
|
enrolment / days 3-5
|
|
- Persisting breathlessness at 28 days and 90 days after enrolment [Time frame 28 days/90 days ]
Time Frame: at 28 day and at 90 day
|
at 28 day and at 90 day
|
|
- Self-reported health at 28 days and 90 days [Time frame 28 days/ 90 days]
Time Frame: at 28 days and 90 days
|
Poor self-reported health assessed by a linear self-reported health scale from the EQ-5D questionnaire in person or by telephone
|
at 28 days and 90 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Effua Usuf, MBChB, PhD, Medical Research Council The Gambia at London School of Hygiene & Tropical Medicine
- Principal Investigator: Behzad Nadjm, MBChB, FRCP, Medical Research Council The Gambia at London School of Hygiene & Tropical Medicine
- Study Director: Anna Roca, PhD, Medical Research Council The Gambia at London School of Hygiene & Tropical Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LEO 22628
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital; Yulin... and other collaboratorsRecruitingCOVID-19 | Post-COVID-19 Syndrome | Post-Acute COVID-19 | Acute COVID-19China
Clinical Trials on Ivermectin
-
Pierre Fabre DermatologyWithdrawn
-
Zydus Worldwide DMCCCatawba Research, LLCCompletedFacial RosaceaUnited States
-
Taro Pharmaceuticals USACompletedLice; Head LiceUnited States
-
Humanis Saglık Anonim SirketiCompleted
-
Mahidol UniversityMinistry of Health, ThailandUnknown
-
Assistance Publique - Hôpitaux de ParisCompletedIvermectin | Gale | Severe Forms of Scabies | Oral Parasitic DrugFrance
-
Actavis Inc.Teva Pharmaceuticals USACompleted
-
Wake Forest University Health SciencesGalderma R&DActive, not recruiting
-
South Valley UniversityRecruiting